Deals
Drugmakers Eye $23 Billion Biotech Argenx Ahead of Key Data
- European firm on the top of major drugmakers’ wish lists
- Takeover interest expected to pick up after July trial results
This article is for subscribers only.
European biotech firm Argenx SE is scheduled to release key drug trial data this summer. Deal-hungry Big Pharma is closely watching.
Several major drugmakers keen to expand in immunology have been studying the $23 billion company for some time and have it at the top of their wish lists, according to people familiar with the matter. Argenx has been working with JPMorgan Chase & Co. to help identify options in the event of any takeover bid, the people said, asking not to be identified because the information is private.